| P50 | author | Caroline Weydert | Q59684805 |
| | Peter Janssens | Q64027061 |
| | Max Christoph Liebau | Q47159237 |
| P2093 | author name string | Djalila Mekahli | |
| | Karl Martin Wissing | |
| | Stephanie De Rechter | |
| P2860 | cites work | Regulation of cAMP production in initial and terminal inner medullary collecting ducts | Q47906259 |
| | Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial | Q47925751 |
| | Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation | Q47980359 |
| | Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment | Q47994672 |
| | Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. | Q51377088 |
| | Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. | Q53600876 |
| | Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). | Q53633509 |
| | Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. | Q53855784 |
| | Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. | Q54367200 |
| | Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. | Q54605466 |
| | Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD) | Q57908853 |
| | Loss of Polycystin-1 in Human Cyst-Lining Epithelia Leads to Ciliary Dysfunction | Q58346974 |
| | Cyst formation and growth in autosomal dominant polycystic kidney disease | Q69071851 |
| | The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease | Q72805639 |
| | Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation | Q73568998 |
| | Somatic inactivation of Pkd2 results in polycystic kidney disease | Q74502174 |
| | Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease | Q76390332 |
| | Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease | Q77998428 |
| | Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist | Q79075547 |
| | ARPKD and ADPKD: first cousins or more distant relatives? | Q80695119 |
| | Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease | Q84415058 |
| | Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back | Q84626176 |
| | The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein | Q24292750 |
| | Liver and kidney disease in ciliopathies | Q24633724 |
| | Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice | Q26767011 |
| | Cilium assembly and disassembly | Q28067455 |
| | Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist | Q28316514 |
| | Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease | Q28586859 |
| | Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases | Q28591325 |
| | Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function | Q28594258 |
| | Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease | Q29037884 |
| | Ciliopathies | Q29614821 |
| | Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience | Q30424687 |
| | Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease | Q42927109 |
| | mTOR inhibitors in polycystic kidney disease. | Q43004248 |
| | Family history of renal disease severity predicts the mutated gene in ADPKD. | Q43074229 |
| | Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin | Q43244326 |
| | Autosomal Recessive Polycystic Kidney Disease: The Clinical Experience in North America | Q44503166 |
| | Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury | Q44633135 |
| | Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. | Q45179997 |
| | Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. | Q45281061 |
| | Vasopressin antagonists in polycystic kidney disease | Q46749574 |
| | Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin | Q46790418 |
| | Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. | Q47741905 |
| | Polyductin undergoes notch-like processing and regulated release from primary cilia | Q30479973 |
| | Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease | Q33571813 |
| | Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again | Q33660700 |
| | Evidence of extraordinary growth in the progressive enlargement of renal cysts | Q33827400 |
| | Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease | Q33872509 |
| | The importance of total kidney volume in evaluating progression of polycystic kidney disease | Q33873107 |
| | Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease | Q33888356 |
| | The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation | Q33974670 |
| | Clinical practice. Autosomal dominant polycystic kidney disease | Q34013969 |
| | Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients | Q34124758 |
| | Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease | Q34148604 |
| | Mutations in multiple PKD genes may explain early and severe polycystic kidney disease | Q34228262 |
| | Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects | Q34321476 |
| | Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation | Q34326684 |
| | Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells | Q34343042 |
| | Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. | Q34355892 |
| | Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials | Q34423262 |
| | Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference | Q34428848 |
| | Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease | Q34529587 |
| | Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. | Q34569800 |
| | Ciliopathies: an expanding disease spectrum | Q34626170 |
| | Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney Disease | Q34639667 |
| | Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. | Q34639673 |
| | Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model | Q34787786 |
| | Blood pressure in early autosomal dominant polycystic kidney disease | Q35129320 |
| | Rationale, design and objectives of ARegPKD, a European ARPKD registry study | Q35176977 |
| | Models of polycystic kidney disease | Q35187032 |
| | Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin | Q35543229 |
| | Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease | Q35667570 |
| | Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. | Q35827271 |
| | Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. | Q35856772 |
| | Vasopressin and disruption of calcium signalling in polycystic kidney disease | Q35962991 |
| | Urea and urine concentrating ability: new insights from studies in mice | Q36093997 |
| | Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. | Q36158232 |
| | The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease | Q36371342 |
| | Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort | Q36616057 |
| | The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. | Q36624712 |
| | Vasopressin directly regulates cyst growth in polycystic kidney disease | Q36667140 |
| | Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. | Q36739229 |
| | TRPP2 and TRPV4 form a polymodal sensory channel complex | Q36817870 |
| | Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies | Q36849194 |
| | Primary cilia are not calcium-responsive mechanosensors | Q36852774 |
| | Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. | Q36917461 |
| | Cyclic nucleotide signaling in polycystic kidney disease | Q37051278 |
| | MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement | Q37152523 |
| | Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome | Q37374452 |
| | Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease | Q37524076 |
| | A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease | Q37529873 |
| | Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease | Q37583266 |
| | Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease. | Q37630699 |
| | Strange as it may seem: the many links between Wnt signaling, planar cell polarity, and cilia | Q37834841 |
| | Planar cell polarity in kidney development and disease | Q37949488 |
| | Congenital nephrogenic diabetes insipidus: the current state of affairs | Q37994652 |
| | Polycystins and cellular Ca2+ signaling | Q38053059 |
| | Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease | Q38067358 |
| | From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease. | Q38076051 |
| | Strategies targeting cAMP signaling in the treatment of polycystic kidney disease | Q38171193 |
| | Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials | Q38181599 |
| | Rationale for early treatment of polycystic kidney disease | Q38229242 |
| | An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases | Q38232593 |
| | Translational research in ADPKD: lessons from animal models | Q38241290 |
| | Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. | Q38255110 |
| | Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. | Q38695316 |
| | Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. | Q38705713 |
| | Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease | Q38733842 |
| | Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease | Q40332825 |
| | Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype | Q40533652 |
| | Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes | Q40844345 |
| | Overexpression of PKD1 causes polycystic kidney disease | Q41780316 |
| | Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease | Q41891142 |
| | Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways | Q42452939 |
| | PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice | Q42512106 |
| P433 | issue | 3 | |
| P921 | main subject | AVP | Q12009087 |
| | kidney disease | Q1054718 |
| P304 | page(s) | 395-408 | |
| P577 | publication date | 2017-04-28 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? | |
| P478 | volume | 33 | |